Natera Looks Compelling As Oncology Testing Momentum Keeps Building [Seeking Alpha]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Seeking Alpha
As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA's 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA's MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA's valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Getty Images Natera, Inc. ( NTRA ) is a diagnostic company that provides molecular testing services. The company's offerings include oncology, women's health, and organ health. Its strongest segment is oncology, particularly minimal residual disease monitoring (MRD). In 2025, NTRA implemented new product launches, obtained new Medicare coverages, and advanced
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal CancersBusiness Wire
- Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis [Yahoo! Finance]Yahoo! Finance
- Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease DiagnosisBusiness Wire
- MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026PR Newswire
- Natera (NTRA) had its price target lowered by Morgan Stanley from $265.00 to $250.00. They now have an "overweight" rating on the stock.MarketBeat
NTRA
Earnings
- 2/26/26 - Miss
NTRA
Sec Filings
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- 3/13/26 - Form 144
- NTRA's page on the SEC website